Kidney Week

Abstract: TH-PO1080

Effects of Pediococcus acidilactici GKA4 Supplementation on Proinflammatory Cytokines in Early-Stage CKD

Session Information

• CKD: Therapeutic Advances
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

• Yang, Wen-Ching, Taichung Veterans General Hospital, Taichung, Taiwan

Wen-Ching Yang, RD, RDN

• Hsieh, Hui-Min, Taichung Veterans General Hospital, Taichung, Taiwan

Hui-Min Hsieh, MS

• Chen, Jun-Peng, Taichung Veterans General Hospital, Taichung, Taiwan

Jun-Peng Chen, MS

• Chen, Yun-Yu, Taichung Veterans General Hospital, Taichung, Taiwan

Yun-Yu Chen, MS

• Pai, Po-Hsin, Taichung Veterans General Hospital, Taichung, Taiwan

Po-Hsin Pai

• Chen, Cheng-Hsu, Taichung Veterans General Hospital, Taichung, Taiwan

Cheng-Hsu Chen, MD, PhD

Background

Chronic kidney disease (CKD) commonly results in elevated levels of proinflammatory cytokines such as TNF-α and IL-6. Although probiotics may modulate these markers in advanced CKD, their effects on early-stage CKD (ECKD) are unclear. This study explored the impact of a specific probiotic on these cytokines in patients with ECKD.

Methods

In this randomized, double-blinded, placebo-controlled trial, individuals with CKD stages G2–3a (eGFR 45–89 mL/min/1.73 m²; ages 20–90 years) were enrolled. Participants were randomly allocated to a probiotic group (Pediococcus acidilactici GKA4) or a control group (placebo) for a six-month treatment period. TNF-α and IL-6 levels were measured in the serum and urine by ELISA, with urinary values adjusted for urine creatinine. Differences between groups were assessed using generalized estimating equations (GEEs).

Results

Eighty patients (median age 57 years; median eGFR 64.1 mL/min/1.73 m²) were included in the intention-to-treat analysis, with 40 patients in each group. No significant differences between the groups in serum and urinary IL-6 or serum TNF-α levels were observed. However, there was a significant decrease in urinary TNF-α levels adjusted for urine creatinine (TNF-α/Cr) in the probiotic group compared to the control group (p = 0.017).

Conclusion

Although probiotic supplementation did not alter serum TNF-α or IL-6 levels, it modulated urinary TNF-α excretion in ECKD patients. Further studies with a larger population are required to confirm the findings.